WebMD Health Corp. (Nasdaq: WBMD), the leading source of health information, announced today its new WebMD Allergy app for the iPhone, an innovative new mobile resource that empowers consumers to take control of their allergies. It is the first free app to provide allergy sufferers with personalized location-based allergy condition forecasts in combination with WebMD’s trusted information and insights. WebMD Allergy is further personalized with optional mobile push notifications that warn when allergen levels are high, enabling app users to proactively manage their allergy conditions.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60044-webmd-introduces-new-allergy-app-for-iphone
Next week at the Consumer Electronics Showcase (CES) in Las Vegas, Neutrogena® will debut sophisticated skin imaging technology that allows consumers to measure what’s happening above and below their skin’s surface. The Neutrogena Skin360™ app and the accompanying SkinScanner powered by FitSkin™ give users an in depth understanding of their skin’s condition and needs, customized advice to address those needs, plus a clear way to track and assess skin’s progress over time.
“Shopping for skincare products can be an overwhelming and confusing experience for our consumer because she is uncertain about what her skin really needs,” said Sebastien Guillon, Global President of Beauty, Johnson & Johnson Consumer. “Smart and connected technology helps us provide our consumer with personalized analyses and information she needs in real time so she can make decisions that will help her achieve her best skin ever.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8250251-neutrogena-skin360-skinscanner-fitskin-ces/
Eye diseases like cataract, glaucoma, detached retina, or myopia all come from weakness and inflammation in the tissues that compose and surround the eye. Most doctors don’t know what to say to you on how you can strengthen and protect your eyes from becoming disease or if you have an eye disease on how to improve your condition
Miramar Labs today announced that the miraDry System for the treatment of primary axillary hyperhidrosis, commonly known as excessive underarm sweat, is now available to select physicians in the U.S. The miraDry procedure provides a safe and lasting solution for this debilitating condition.
The U.S. Food & Drug Administration granted clearance for miraDry following a robust, randomized, blinded clinical study that involved 120 patients at seven clinics and followed them 12-months post treatment. The miraDry System delivers energy non-invasively to the area under the arm where the sweat glands reside which creates localized heat to destroy and eliminate the glands. Since sweat glands do not regenerate, results are lasting.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54021-miramar-labs-miradry-treat-excessive-underarm-sweat-axillary-hyperhidrosis
Duchesnay USA launched a new online video series today about pregnancy health and morning sickness, which many don’t know is a medical condition called Nausea and Vomiting of Pregnancy (NVP). The series, entitled Navigating Morning Sickness, premiered with three videos about pregnancy nutrition, medication safety and the potential impact of NVP on a pregnant woman’s life. Additional new videos will be released throughout November and December.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64373-duchesnay-usa-online-video-series-pregnancy-morning-sickness
Top of the mountain, five percent battery remaining, no outlet in sight. Decision time: go back or keep going? Adventurers can now go further in almost any condition with FRĒ Power from LifeProof, doubling the battery life of iPhone 6.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7525051-lifeproof-announces-fre-power/
LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today recognizes that more than one million people in the United States with drug-resistant epilepsy continue to be treated unsuccessfully with drugs, despite the proven effectiveness of non-drug treatment options. LivaNova’s VNS Therapy®, for example, is a medical device treatment specifically designed for people with drug-resistant epilepsy that is already used by more than 85,000 people around the world.
One in three people with epilepsy has the type that is not well controlled with drugs, called drug-resistant epilepsy. For those people, prescribing more medicine is usually not the most effective option. In fact, research shows that if you haven’t found seizure freedom after your first two drugs, there is a 95 percent chance that no drug or combination of drugs will result in seizure freedom.
“Despite what we know about drug-resistant epilepsy, the majority of people affected by this condition will continue to be prescribed additional medications instead of being evaluated for surgery or seen in a specialized epilepsy facility,” said Jason Richey, president of LivaNova’s U.S. Region and general manager of the Neuromodulation Business Franchise. “This treatment gap means over one million individuals in the U.S. with undertreated epilepsy remain at risk for dangerous side effects of continued seizures, including injury, depression, memory issues and death.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7966451-livanova-vns-therapy-epilepsy/
A new survey from Alcon, the global leader in eye care and a division of Novartis, demonstrates that people experience significant emotional and lifestyle benefits after cataract surgery. Nearly three in four respondents who expressed an opinion agreed that after having the surgery, they were happier, more satisfied and had a greater appreciation for life. The survey also confirmed that life before surgery posed several daily challenges. A majority of survey respondents said cataracts made simple, day-to-day tasks harder, and made them feel annoyed, frustrated and old.
In recognition of Cataract Awareness Month this June, Alcon conducted the MyCataracts survey with 1,300 US adults, age 60 and over, who have undergone cataract surgery, to better understand the emotional journey of the condition and the lifestyle benefits of treatment. The survey expands Alcon’s ongoing MyCataracts awareness campaign by uncovering insights that will help people make informed treatment decisions together with their doctors.
To view the multimedia release go to:
https://www.multivu.com/players/English/8068751-alcon-pharmaceuticals-my-cataracts-eye-care/
The American Kidney Fund today launches a national campaign to raise awareness about kidney disease, a serious and increasingly common condition that is damaging the health of as many as 31 million Americans. Pair Up: Join the Fight to Prevent Kidney Disease encourages women to take two simple, yet powerful actions: learn if they’re at risk for kidney disease; and spread the word about kidney disease to loved ones who also may be at risk. The launch of Pair Up coincides with the release of a national survey revealing that most Americans who care for their loved ones’ health are unaware that diabetes and high blood pressure are the leading causes of kidney disease.
To view Multimedia News Release, go to http://www.multivu.com/mnr/51973-american-kidney-fund-laila-ali-pair-up-women-prevent-kidney-disease
On World Mental Health Day, Janssen has announced the results of a pan-European research project: ‘Talking About Treatment in Schizophrenia: A Patient and Carer Survey’. The survey of 166 adults living with schizophrenia and 468 carers was conducted by the independent market research agency, Fieldwork International (part of Ipsos MORI), and explored awareness, feelings and preferences regarding treatment.
The survey, conducted across 12 countries in Europe (Austria, Belgium, Denmark, France, Germany, Italy, Netherlands, Russia, Spain, Sweden, Switzerland and the UK), highlighted key factors affecting the peace of mind for carers, such as the impact of the condition on day‑to-day life, potential relapse/hospitalisation and getting support beyond medication. 94% stated they reminded the person they care for to take their medication and for 49% this happens often.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7947151-janssen-survey-carers-adults-schizophrenia/
